Although our emphasis was on the intratumoral immune environment, it has been reported that soluble PD-1 and PD-L1 also play a role in modulating anti-tumor immunity and the efficacy of anti-PD-1 therapy [18,19,20]. This evidence concerns the gene CD274 and neoplasm.